Skip to main content
Clinical Trials/EUCTR2022-003855-32-SE
EUCTR2022-003855-32-SE
Active, not recruiting
Phase 1

An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Ritanovir in Non-hospitalized Adult Participants suffering from post-COVID

Karolinska Institutet0 sites400 target enrollmentJanuary 31, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with Post-Acute COVID syndrome (PACS) in which extensive clinical and biochemical examinations have been performed. PACS patients experience a wide variety of symptoms related to physical and cognitive function, including fatigue, dyspnea, brain fog” or other cognitive symptoms, pain, depression, and gastrointestinal issues which significantly impact quality of life.
Sponsor
Karolinska Institutet
Enrollment
400
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 31, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients, \=18 years of age, diagnosed with post\-acute COVID\-19 syndrome, with reported EQ\-5D\-5L VAS\<50
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 350
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 50

Exclusion Criteria

  • Acute COVID\-19 infection, other non\-related conditions with post\-acute COVID\-19 syndrome like symptoms, previous treatment with Paxlovid

Outcomes

Primary Outcomes

Not specified

Similar Trials